Cargando…
Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
BACKGROUND: Carbapenems and β-lactam and β‐lactamase inhibitors (BLBLIs) have been used empirically in nosocomial pneumonia, but their efficacy and safety are controversial. OBJECTIVE: We carried out a systematic review with meta-analysis to evaluate the efficacy and safety of carbapenems versus BLB...
Autores principales: | Cang, Huai Qin, Quan, Xiang Hua, Chu, Xiang Hua, Liang, Yu, Yang, Xue, Li, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520732/ https://www.ncbi.nlm.nih.gov/pubmed/37767465 http://dx.doi.org/10.1016/j.heliyon.2023.e20108 |
Ejemplares similares
-
Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia
por: Lin, Wei-Ting, et al.
Publicado: (2019) -
Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022) -
Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
por: Reddy, Nakita, et al.
Publicado: (2023) -
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021) -
In Vitro and
In Vivo Development of a β-Lactam-Metallo-β-Lactamase
Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
por: Peters, Byron K., et al.
Publicado: (2023)